NYSE · LLY
Eli Lilly and Company
$1,427.46+$53.76 (+3.91%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.57% below the high.
Loading market information…
NASDAQ · APEN · USD
Stock price, earnings
Quote as of Apr 3, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Apollo Endosurgery, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.91% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Apollo Endosurgery, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Apollo Endosurgery, Inc. is a medical technology firm specializing in the creation, development, and commercialization of advanced medical instruments. Among its products are the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which empower physicians to perform advanced endoscopic procedures by suturing and securing tissue approximation via a flexible endoscope. The company also features the Orbera intragastric balloon system, available under brands such as Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System. This system aids in weight management by decreasing stomach capacity and slowing gastric emptying, thereby encouraging reduced food intake. Additionally, it provides the X-Tack Endoscopic HeliX Tacking System, a suture-based device designed for repairing defects in both the upper and lower gastrointestinal tract. Its medical solutions are distributed to various healthcare providers, including hospitals, outpatient surgical centers, clinics, and individual physicians, across the United States, Australia, Costa Rica, and several European nations. Founded in 2005, Apollo Endosurgery, Inc. maintains its headquarters in Austin, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:07 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2021 |
|---|
| Aug 3, 2021 |
| -$0.11+45.0% vs estimate |
| $16.61M0.0% vs estimate |
| Q1 2021 | May 4, 2021 | -$0.17+22.73% vs estimate | $13.86M-18.52% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,427.46+$53.76 (+3.91%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.57% below the high.
$276.66+$1.46 (+0.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 1.85% below the high.
$22.18-$1.26 (-5.38%)
Artivion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.03% below the high.
$12.45-$0.38 (-2.96%)
Integra LifeSciences Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 39.25% below the high.
$18.42-$0.02 (-0.11%)
Varex Imaging Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.13% below the high.
$2.82-$0.35 (-10.95%)
Pulmonx Corporation’s quoted price sits in the upper half of its reported 52-week range, 13.28% below the high.
$2.55-$0.14 (-5.2%)
Apyx Medical Corporation’s quoted price sits in the lower half of its reported 52-week range, 49.8% below the high.
$0.68-$0.00 (-0.08%)
PetVivo Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.7% below the high.
